Literature DB >> 19766801

Incidence and patterns of adverse event onset during the first 60 days after ventricular assist device implantation.

Elizabeth A Genovese1, Mary Amanda Dew, Jeffrey J Teuteberg, Marc A Simon, Joy Kay, Michael P Siegenthaler, Jay K Bhama, Christian A Bermudez, Kathleen L Lockard, Steve Winowich, Robert L Kormos.   

Abstract

BACKGROUND: Although ventricular assist devices (VADs) provide effective treatment for end-stage heart failure, VAD support remains associated with significant risk for adverse events (AEs). To date there has been no detailed assessment of the incidence of a full range of AEs using standardized event definitions. We sought to characterize the frequency and timing of AE onset during the first 60 days of VAD support, a period during which clinical observation suggests the risk of incident AEs is high.
METHODS: A retrospective analysis was performed utilizing prospectively collected data from a single-site clinical database including 195 patients aged 18 or greater receiving VADs between 1996 and 2006. Adverse events were coded using standardized criteria. Cumulative incidence rates were determined, controlling for competing risks (death, transplantation, recovery-wean).
RESULTS: During the first 60 days after implantation, the most common AEs were bleeding, infection, and arrhythmias (cumulative incidence rates, 36% to 48%), followed by tamponade, respiratory events, reoperations, and neurologic events (24% to 31%). Other events (eg, hemolysis, renal, hepatic events) were less common (rates <15%). Some events (eg, bleeding, arrhythmias) showed steep onset rates early after implantation. Others (eg, infections, neurologic events) had gradual onsets during the 60-day period. Incidence of most events did not vary by implant era (1996 to 2000 vs 2001 to 2006) or by left ventricular versus biventricular support.
CONCLUSIONS: Understanding differential temporal patterns of AE onset will allow preventive strategies to be targeted to the time periods when specific AE risks are greatest. The AE incidence rates provide benchmarks against which future studies of VAD-related risks may be compared.

Entities:  

Mesh:

Year:  2009        PMID: 19766801      PMCID: PMC2763436          DOI: 10.1016/j.athoracsur.2009.06.028

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  34 in total

1.  Mechanical circulatory support device database of the International Society for Heart and Lung Transplantation: third annual report--2005.

Authors:  Mario C Deng; Leah B Edwards; Marshall I Hertz; Amanda W Rowe; Berkeley M Keck; Robert Kormos; David C Naftel; James K Kirklin; David O Taylor
Journal:  J Heart Lung Transplant       Date:  2005-09       Impact factor: 10.247

2.  Mechanical circulatory support therapy as a bridge to transplant or recovery (new advances).

Authors:  James K Kirklin; William L Holman
Journal:  Curr Opin Cardiol       Date:  2006-03       Impact factor: 2.161

3.  Long-term destination therapy with the HeartMate XVE left ventricular assist device: improved outcomes since the REMATCH study.

Authors:  James W Long; Abdallah G Kfoury; Mark S Slaughter; Marc Silver; Carmelo Milano; Joseph Rogers; Reynolds Delgado; O H Frazier
Journal:  Congest Heart Fail       Date:  2005 May-Jun

4.  Use of a continuous-flow device in patients awaiting heart transplantation.

Authors:  Leslie W Miller; Francis D Pagani; Stuart D Russell; Ranjit John; Andrew J Boyle; Keith D Aaronson; John V Conte; Yoshifumi Naka; Donna Mancini; Reynolds M Delgado; Thomas E MacGillivray; David J Farrar; O H Frazier
Journal:  N Engl J Med       Date:  2007-08-30       Impact factor: 91.245

5.  Cerebrovascular accidents in patients with a ventricular assist device.

Authors:  Hiroyuki Tsukui; Adib Abla; Jeffrey J Teuteberg; Dennis M McNamara; Michael A Mathier; Linda M Cadaret; Robert L Kormos
Journal:  J Thorac Cardiovasc Surg       Date:  2007-06-04       Impact factor: 5.209

6.  Improving outcomes with long-term "destination" therapy using left ventricular assist devices.

Authors:  James W Long; Aaron H Healy; Brad Y Rasmusson; Cris G Cowley; Karl E Nelson; Abdallah G Kfoury; Stephen E Clayson; Bruce B Reid; Stephanie A Moore; Douglas U Blank; Dale G Renlund
Journal:  J Thorac Cardiovasc Surg       Date:  2008-06       Impact factor: 5.209

7.  A prospective, multicenter trial of the VentrAssist left ventricular assist device for bridge to transplant: safety and efficacy.

Authors:  Donald Esmore; David Kaye; Phillip Spratt; Robert Larbalestier; Peter Ruygrok; Steven Tsui; Deborah Meyers; Arnt E Fiane; John Woodard
Journal:  J Heart Lung Transplant       Date:  2008-04-23       Impact factor: 10.247

8.  Chronic mechanical circulatory support for inotrope-dependent heart failure patients who are not transplant candidates: results of the INTrEPID Trial.

Authors:  Joseph G Rogers; Javed Butler; Steven L Lansman; Alan Gass; Peer M Portner; Michael K Pasque; Richard N Pierson
Journal:  J Am Coll Cardiol       Date:  2007-08-06       Impact factor: 24.094

9.  Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection.

Authors:  Katherine Lietz; James W Long; Abdallah G Kfoury; Mark S Slaughter; Marc A Silver; Carmelo A Milano; Joseph G Rogers; Yoshifumi Naka; Donna Mancini; Leslie W Miller
Journal:  Circulation       Date:  2007-07-16       Impact factor: 29.690

10.  Evaluation of the clinical effectiveness of the Ventricular Assist Device Program in the United Kingdom (EVAD UK).

Authors:  Linda D Sharples; Fay Cafferty; Nickolaos Demitis; Carol Freeman; Matthew Dyer; Nicholas Banner; Emma J Birks; Asghar Khaghani; Stephen R Large; Steven Tsui; Noreen Caine; Martin Buxton
Journal:  J Heart Lung Transplant       Date:  2007-01       Impact factor: 10.247

View more
  32 in total

1.  Survival benefit of implantable cardioverter-defibrillators in left ventricular assist device-supported heart failure patients.

Authors:  Marwan M Refaat; Toshikazu Tanaka; Robert L Kormos; Dennis McNamara; Jeffrey Teuteberg; Steve Winowich; Barry London; Marc A Simon
Journal:  J Card Fail       Date:  2011-12-22       Impact factor: 5.712

Review 2.  The use of computational fluid dynamics in the development of ventricular assist devices.

Authors:  Katharine H Fraser; M Ertan Taskin; Bartley P Griffith; Zhongjun J Wu
Journal:  Med Eng Phys       Date:  2010-11-13       Impact factor: 2.242

3.  Preoperative patient optimization for mechanical circulatory support.

Authors:  Brian A Houston; Stuart D Russell
Journal:  Ann Cardiothorac Surg       Date:  2014-11

4.  Biventricular assist device terminates polymorphic ventricular tachycardia in giant cell myocarditis.

Authors:  Hannah Raasch; Ross J Simpson
Journal:  Tex Heart Inst J       Date:  2012

Review 5.  Ventricular Arrhythmias in Patients With Left Ventricular Assist Device (LVAD).

Authors:  Azza Ahmed; Mustapha Amin; Barry A Boilson; Ammar M Killu; Malini Madhavan
Journal:  Curr Treat Options Cardiovasc Med       Date:  2019-11-27

Review 6.  Understanding the C-pulse device and its potential to treat heart failure.

Authors:  Virna L Sales; Patrick M McCarthy
Journal:  Curr Heart Fail Rep       Date:  2010-03

7.  Postoperative atrial fibrillation is associated with increased morbidity and resource utilization after left ventricular assist device placement.

Authors:  Robert B Hawkins; J Hunter Mehaffey; Abra Guo; Eric J Charles; Alan M Speir; Jeffrey B Rich; Mohammed A Quader; Gorav Ailawadi; Leora T Yarboro
Journal:  J Thorac Cardiovasc Surg       Date:  2018-04-18       Impact factor: 5.209

8.  A quantitative comparison of mechanical blood damage parameters in rotary ventricular assist devices: shear stress, exposure time and hemolysis index.

Authors:  Katharine H Fraser; Tao Zhang; M Ertan Taskin; Bartley P Griffith; Zhongjun J Wu
Journal:  J Biomech Eng       Date:  2012-08       Impact factor: 2.097

9.  Early adverse events as predictors of 1-year mortality during mechanical circulatory support.

Authors:  Elizabeth A Genovese; Mary Amanda Dew; Jeffrey J Teuteberg; Marc A Simon; Jay K Bhama; Christian A Bermudez; Kathleen L Lockard; Steve Winowich; Robert L Kormos
Journal:  J Heart Lung Transplant       Date:  2010-07-01       Impact factor: 10.247

10.  Severe hemolytic anemia caused by the NIPRO extracorporeal left ventricular assist device.

Authors:  Ikuko Shibasaki; Toshiyuki Kuwata; Go Tsuchiya; Hironaga Ogawa; Yasuyuki Yamada; Shigeru Toyoda; Teruo Inoue; Hirotsugu Fukuda
Journal:  Gen Thorac Cardiovasc Surg       Date:  2016-01-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.